Drug intelligence / Profile preview

bevacizumab + candesartan + pemetrexed

Development stage: Preclinical
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of bevacizumab (a monoclonal antibody targeting VEGF-A), candesartan (an angiotensin II receptor blocker), and pemetrexed (an antifolate chemotherapy agent). This combination is designed to attack multiple synthetic lethal vulnerabilities in cancer treatment.

Other names: PBC

Targets

DHFR (Dihydrofolate reductase)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on bevacizumab + candesartan + pemetrexed.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bevacizumab + candesartan + pemetrexed.

Explore the full profile